VistaGen Therapeutics Inc Cash Flow Conversion Efficiency
VistaGen Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, VistaGen Therapeutics Inc (VTGN) has a cash flow conversion efficiency ratio of -0.456x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.20 Million) by net assets ($35.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of VistaGen Therapeutics Inc (2008–2026)
Cash flow conversion efficiency of VistaGen Therapeutics Inc from 2008 to 2026. This chart illustrates how VistaGen Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest VistaGen Therapeutics Inc stock price today for real-time trading data and today's change.
VistaGen Therapeutics Inc Cash Flow Conversion Ratio Explained
VistaGen Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
VistaGen Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of VistaGen Therapeutics Inc ranked by their cash flow conversion efficiency. Also see how much is VistaGen Therapeutics Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Broadband Technology Co Ltd
SHG:600608
|
0.540x |
|
ECP Emerging Growth Ltd
AU:ECP
|
-0.023x |
|
Neuroone Medical Technologies Corp
NASDAQ:NMTC
|
-0.247x |
|
Sarama Resources Ltd
AU:SRR
|
0.465x |
|
Costain Group PLC
LSE:COST
|
0.044x |
|
Warisan TC Holdings Bhd
KLSE:5016
|
0.095x |
|
Tedea Technological Development and Automation Ltd
TA:TEDE
|
3.252x |
|
Aumake Ltd
AU:AUK
|
0.022x |
Annual Cash Flow Conversion Efficiency for VistaGen Therapeutics Inc (2008–2026)
The table below shows the annual cash flow conversion efficiency of VistaGen Therapeutics Inc from 2008 to 2026. Review VistaGen Therapeutics Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $35.52 Million | $-66.44 Million | -1.870x | -212.74% |
| 2025-03-31 | $70.39 Million | $-42.10 Million | -0.598x | -164.79% |
| 2024-03-31 | $114.29 Million | $-25.81 Million | -0.226x | +94.51% |
| 2023-03-31 | $12.08 Million | $-49.72 Million | -4.115x | -488.50% |
| 2022-03-31 | $64.72 Million | $-45.26 Million | -0.699x | -432.75% |
| 2021-03-31 | $91.98 Million | $-12.07 Million | -0.131x | -104.77% |
| 2020-03-31 | $-5.73 Million | $-15.76 Million | 2.750x | +233.94% |
| 2019-03-31 | $7.08 Million | $-14.53 Million | -2.053x | -56.78% |
| 2018-03-31 | $6.92 Million | $-9.06 Million | -1.310x | +88.89% |
| 2017-03-31 | $615.80K | $-7.26 Million | -11.793x | -830.16% |
| 2016-03-31 | $-2.98 Million | $-4.81 Million | 1.615x | +1098.27% |
| 2015-03-31 | $-20.54 Million | $-2.77 Million | 0.135x | -18.85% |
| 2014-03-31 | $-12.80 Million | $-2.13 Million | 0.166x | -39.78% |
| 2013-03-31 | $-12.56 Million | $-3.46 Million | 0.276x | -55.87% |
| 2012-03-31 | $-5.71 Million | $-3.57 Million | 0.625x | -90.91% |
| 2011-03-31 | $-1.00K | $-6.88K | 6.878x | -96.25% |
| 2010-03-31 | $-124.00 | $-22.76K | 183.516x | +26003.82% |
| 2009-03-31 | $20.37K | $-14.43K | -0.708x | -102.13% |
| 2008-03-31 | $-145.00 | $-4.81K | 33.200x | -- |
About VistaGen Therapeutics Inc
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an od… Read more